Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9304MR)

This product GTTS-WQ9304MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9304MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14918MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ11299MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ3282MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ2738MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ14334MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ10542MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ1819MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ8999MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMA-638
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW